Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

Journal of the National Comprehensive Cancer Network : JNCCN
Douglas B JohnsonJason J Luke

Abstract

Background: Uveal melanoma (UM) is an uncommon melanoma subtype with poor prognosis. Agents that have transformed the management of cutaneous melanoma have made minimal inroads in UM. Methods: We conducted a single-arm phase II study of pembrolizumab in patients with metastatic UM and performed bioinformatics analyses of publicly available datasets to characterize the activity of anti-PD-1 in this setting and to understand the mutational and immunologic profile of this disease. Results: A total of 5 patients received pembrolizumab in this study. Median overall survival was not reached, and median progression-free survival was 11.0 months. One patient experienced a complete response after one dose and 2 others experienced prolonged stable disease (20% response rate, 60% clinical benefit rate); 2 additional patients had rapidly progressing disease. Notably, the patients who benefited had either no liver metastases or small-volume disease, whereas patients with rapidly progressing disease had bulky liver involvement. We performed a bioinformatics analysis of The Cancer Genome Atlas for UM and confirmed a low mutation burden and low rates of T-cell inflammation. Note that the lack of T-cell inflammation strongly correlated with MYC...Continue Reading

Associated Clinical Trials

Feb 10, 2015·Douglas Johnson, Douglas Johnson

References

May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
Nov 3, 2016·Cancer Immunology Research·Douglas B JohnsonChristine M Lovly
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Stefani SprangerThomas F Gajewski
Jun 27, 2017·The Journal of Clinical Investigation·Mark AyersTerrill K McClanahan
Aug 16, 2017·Cancer Cell·A Gordon RobertsonScott E Woodman
Jan 13, 2018·Nature Reviews. Cancer·Stefani Spranger, Thomas F Gajewski

❮ Previous
Next ❯

Citations

Feb 6, 2020·International Journal of Molecular Sciences·Anja WesselyMarkus Vincent Heppt
Jun 26, 2020·Journal for Immunotherapy of Cancer·Yana G NajjarAlexander Shoushtari
Jul 25, 2019·Cancers·Bertil E DamatoRichard D Carvajal
Jul 17, 2020·OncoTargets and Therapy·Yi Fan LiWen Bin Wei
Oct 1, 2020·Cancers·Fabiana MalloneAntonietta Moramarco
Feb 13, 2020·Current Oncology Reports·Christopher G TwittyAdil I Daud
Sep 29, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jason J LukeGary K Schwartz
Jan 9, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José María PiulatsAlfonso Berrocal-Jaime
Nov 6, 2020·Therapeutic Advances in Medical Oncology·Yongyun LiXianqun Fan
Mar 3, 2021·Expert Opinion on Investigational Drugs·Christos MasaoutisStamatios Theocharis
Jun 22, 2021·Frontiers in Oncology·Naoki TakahashiIchiro Yasuda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Related Papers

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Camila Toledo StaunerSebastian Haferkamp
Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva
P Sánchez-PobreJ A Solís-Herruzo
Melanoma Research
Muhammad Adnan KhattakJames Larkin
© 2022 Meta ULC. All rights reserved